Stockholder News: 2008 Archives

Melville, New York, June 22, 2009 — Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced it was selected to be part of the Russell 2000®, Russell 3000® and Russell Global Indexes when the Russell Investment Group reconstitutes its family of U.S. indexes on June 26th, according to a preliminary list of additions posted Friday, June 19th on www.russell.com.

Membership in the Russell Indexes, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

Annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000® Index and Russell Microcap. The largest 1,000 companies in the ranking comprise the large-cap Russell 1000® Index and the next 2,000 companies become the widely used small-cap Russell 2000® Index. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, May 8, 2009 - Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2009.

First quarter revenues increased 8.1% to a first quarter record $7.2 million compared to $6.7 million recorded in the same period last year; resulting in net income of $403,266 or $.02 per diluted share versus net income of $190,444 or $.01 per diluted share in the prior year. Gross Profit margins increased to 46% during the first quarter from 39% in last year’s first quarter. Both revenue and gross profit margin increases were primarily attributable to an increase in sales of disposable products.

Andrew Makrides, president of Bovie, stated, “We are pleased to report an increase in revenues and earnings in the first quarter despite the economic downturn. As previously reported, the Company submitted an application to the FDA regarding J-Plasma and is currently working toward 510K submission for the BOSS orthopedic tissue resection device and our Polarian vessel sealing technology, each of which we believe can significantly impact future revenues.”

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

BOVIE MEDICAL CORPORATION CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE MONTH PERIOD (UNAUDITED)
	Three Months Ending March 31, 2009
	2009	2008
Revenues	$7,217,324	$6,677,567
Cost of sales	$3,897,510	$4,091,642
Gross profit	$3,319,814	$2,585,925
Totalcost & expense	$2,777,156	$2,296,977
Income from operations	$542,658	$288,948
Interest income, net	$67,608	$21,727
Income before income taxes	$610,266	$310,675
Provision for income taxes	$(207,000)	$(120,231)
Net income	$403,266	$190,444
Earnings per common share Basic Diluted	$0.02 $0.02	$0.01 $0.01
Weighted average number of shares outstanding	16,852,994	15,922,863
Weighted average number of shares outstanding adjusted for dilutive securities	17,777,738	17,684,783

Melville, New York, April 24, 2009 - Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced Dr. Peter Pardoll, a board certified gastroenterologist, has been elected to Bovie’s board of directors. Dr. Pardoll succeeds Randy Rossi who resigned in March 2009.

Dr. Pardoll has a diverse background in medicine. He is an active member of the National Association of Healthcare Consultants and the founding past managing partner of the Center for Digestive Diseases (CDD) in St. Petersburg, Florida. Dr. Peter Pardoll is the president of Medical Education Associates (MEA), a healthcare consulting group. Dr. Pardoll is a past trustee of the Board of the American College of Gastroenterology and past president of the Florida Gastroenterology Society.

Andrew Makrides, president of Bovie, stated, “I am pleased to welcome Dr. Pardoll to our board. He has long been recognized in the healthcare field witnessed by his inclusion from 1996 to 2005 being honored and elected to “The Best Doctors in America.”

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, April 13, 2009 - Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the appointment of David Uffer as Vice President of Advanced Technologies and Director of Plasma sales and marketing. Mr. Uffer comes to Bovie with 18 years experience in the medical products industry. He has been extensively involved in several new product introductions including: supervising and staffing sales representatives, developing worldwide marketing plans, creating customer training modules, accessing clinical trials and establishing strategic partnerships.

Andrew Makrides, president of Bovie, stated, “David is a welcome addition to Bovie’s management team. His experience with new product launches should accelerate J-Plasma’s entree into the marketplace.”

Management believes that J-Plasma has potential in several surgical specialties including dermatology and plastic surgery. In addition, we are encouraged by the feedback from our participation and presentation at the International Conference on Plasma Medicine in March 2009. The conference, technical in scope, provided the Company an excellent opportunity to assess the current status of plasma medicine.

As previously reported on March 3, 2009, Bovie submitted a 510(K) pre-market notification application to the U.S. Food and Drug Administration (FDA).

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website HYPERLINK "http://www.boviemedical.com" www.boviemedical.com.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, March 13, 2009 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced fourth quarter and fiscal 2008 financial results.

Fourth quarter revenues totaled $7.1 million compared to $7.2 million recorded in the same period last year; resulting in net income of $38,767 or $.00 per diluted share versus net income of $125,778 or $.01 per diluted share in the prior year. The Company finished 2008 strongly with December being the highest sales month in Bovie’s history.

For the fiscal year ended December 31, 2008 revenues were $28.1 million compared to $28.8 million reported for 2007. Net income totaled $1,831,788 or $.11 per diluted share versus net income of $2,245,591 or $.13 per diluted share comparable period last year. Gross profit margins increased by 3% during 2008 due to an improved product mix. Research and development expenses increased $418,000 primarily due to costs relating to the development of new products.

New Product Update:

Management is encouraged by the positive reception of our new SEER tissue resection device and has established a direct and specialty sales team already resulting in initial orders. A 510(k) FDA application for the BOSS orthopedic device, an expansion and companion of SEER, is tentatively planned to be submitted in the near future.
The recent 510(k) application for our ICON GS/J-Plasma system includes an improved generator and handpiece with several new features that should increase efficiency for the physician and surgeon, while reducing manufacturing costs. Management is developing a marketing strategy for the ICON GS, a product we believe to be versatile with possible uses in several surgical specialties.
Bovie Canada continues to direct efforts to finalize development of its MEG line and Polarian vessel sealing instruments. The submission of a 510(k) FDA application for Polarian is scheduled to be completed in the next several months.

Andrew Makrides, president of Bovie, stated, “We are pleased 2008 showed real progress in the development of our new products featured by the marketing entry of our SEER tissue resection device. Our core business remained strong highlighted by a record sales month for December 2008 and sales increases in January and February 2009 over the corresponding months in 2008.

While no agreements have concluded to date, discussions continue with other companies regarding the possibility of strategic partnerships.”

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

BOVIE MEDICAL CORPORATION CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE AND TWELVE-MONTH PERIODS(AUDITED)
	Three Months Ending December 31st		Year Ending December 31st
	2008	2007	2008	2007
Revenues	$7,137,838	$7,177,096	$28,096,510	$28,779,157
Cost of Sales	$4,008,777	$4,520,743	$16,247,702	$17,463,644
Gross Profit	$3,129,061	$2,656,353	$11,848,808	$11,315,513
Cost & Expense	$2,985,740	$2,242,145	$10,557,530	$9,209,007
Gain (loss) from Operations	$143,321	$414,208	$1,291,278	$2,106,506
Other Income (expense) Interest (net of expense)	$(25,131)	$43,927	$1,485,933	$145,250
Income Before Minority Interest and Income Taxes	$118,190	$458,135	2,777,211	$2,251,756
Minority Interest and Income Taxes	$(79,423)	$(332,357)	$(945,423)	$(6,165)
Net Income (loss) EPS (loss) Basic EPS (loss) Diluted	$38,767 .00 .00	$125,778 .01 .01	$1,831,788 .11 .11	$2,245,591 .15 .13
Weighted Average Shares Outstanding	16,288,878	15,444,613	16,071,229	15,324,508
Weighted Average Shares Adjusted for Dilutive Securities	17,261,999	17,773,579	17,086,798	17,684,705

Melville, New York, March 3, 2009 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its ICON GS electrosurgical generator and handpiece
(J-Plasma system).

The technology utilizes a gas ionization process producing a stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon greater precision, minimal invasiveness and an absence of conductive currents during surgery. Recent engineering improvements include increases in power and efficiency and component miniaturization, making manufacturing easier and more efficient.

Mr. Makrides president of Bovie Medical commented, “Since the 2007 acquisition giving Bovie total ownership of J-Plasma, the Company has dynamically changed and improved the device. By incorporating Bovie’s ICON technology as a platform for J-Plasma, we have enhanced the flexibility of the product as well as its potential applications.”

Management is considering possible uses in several surgical procedures including dermatology and plastic surgery as well as several other surgical specialties.

The Company will be attending and presenting its plasma technology at the second annual International Conference on Plasma Medicine at the Tropicano Riverwalk Hotel, San Antonio, TX. March 16th-20th. According to the conferences website (http://plasma.mem.drexel.edu/icpm-2/), the International Conference on Plasma Medicine brings together plasma scientists, medical doctors, biologists and biochemists to share fascinating results of their research and share latest developments in plasma medicine, a new field at the intersection of plasma science, biology and medicine.

Conference Topics: Fundamentals of interaction between plasma and living systems; plasma sterilization; plasma wounds treatment; plasma blood coagulation; plasma cancer treatment; new applications of plasma in medicine; design of plasma systems for medical applications; physics of plasma discharges in medicine; plasma chemistry in medicine.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, February 19, 2009 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced that the Company has completed numerous successful surgical procedures with its SEER tissue resection device in France, Italy, Belgium, Spain and in the United States. Sales of the product have commenced in both the U.S. and abroad.

The SEER utilizes RF energy and saline together with Bovie’s proprietary technology to create a distinct clinical effect that has been initially used in solid organ resection to cut tissue and limit blood loss while improving surgeon visibility and patient outcomes.

Since the SEER’s 510K clearance from the FDA in November 2008, the Company has employed three direct sales representatives and two specialty distributors dedicated to SEER sales. Regarding sales in the European Union, Bovie utilizes specialty distributors managed by Johan Segers who directs sales and marketing efforts for Europe and the Middle East.

The worldwide market size for tissue coagulation is estimated to exceed $500 million, and with the advent of Bovie’s new BOSS technology, management is focused on large and growing opportunities driven by an aging population. The BOSS technology, an expansion of the SEER technology, is especially designed for reducing blood loss during orthopedic surgery. The technology will address hip, knee and spinal fusion surgeries estimated to be over one million performed annually, and projected to grow at a rate of over 5 percent per annum.

Andrew Makrides, president of Bovie, commented that we are highly encouraged by surgeon responses to the SEER and the Company anticipates reporting on the BOSS and other product developments in coming weeks.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, November 19, 2008 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company received 510(k) clearance from the Food and Drug Administration (FDA) to market its SEER tissue resection device intended for initial use in liver oncology surgery. The SEER device uses conductive sintered steel as an electrode for radio frequency (RF) for cutting and coagulation. The process involves delivery of RF current and sterile saline for resection and coagulation in surgical procedures. The Company anticipates developing additional products based on the SEER technology for use in orthopedic and blood vessel sealing procedures. The worldwide market size for the liver and orthopedic market is expected to total $500 million in 2009.

Andrew Makrides, president of Bovie stated, “We are pleased to have received FDA 510(k) clearance to market the SEER device in the United States having already CE Marked the product for sale in the European Union. Bovie’s ability to market the SEER positions the Company closer to its goal of increasing shareholder value through the development of proprietary technologies and products.”

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website, www.boviemedical.com.

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, November 17, 2008 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced the closing of an Industrial Revenue Bond (IRB) offering by the Pinellas County Development Authority (Florida) on behalf of Bovie in the amount of $4,000,000. The bond is covered by a letter of credit by Royal Bank of Canada. The proceeds of the IRB substantially satisfied the balance on the Company’s line of credit used to purchase a larger facility in Largo, FL. The new facility allows the Company to consolidate its operations and provides for its future growth needs. The Company during the next several months will make available for sale its current premises in St. Petersburg, FL.

Gary Pickett, chief financial officer of Bovie, stated, “Bovie’s ability to access the capital markets at this time, especially the credit market, demonstrates investor confidence in Bovie’s future. The benefits of our IRB include: long term financing at interest rates below conventional financing and eliminating any current short term debt. We look forward to justifying this confidence as we transform Bovie from an OEM dependent company to one with a broad portfolio of proprietary products and technologies.”

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website, www.boviemedical.com.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, November 10, 2008 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced third quarter and nine month results for the period ended September 30, 2008.

Third quarter revenues were $7,295,793 compared to $7,459,818 recorded in the same period of 2007. Net income was $365,890 or $.02 per diluted share versus net income of $471,636 or $.03 per diluted share in the prior year. Lower third quarter OEM sales were partially offset by an improved product mix, which contributed to a three percent increase in gross profit margins.

Nine month revenues were $20,958,672 compared to $21,602,061 reported during the first nine months of 2007. Net income totaled $1,793,021 or $.10 per diluted share versus net income of $2,119,813 or $.12 per diluted share comparable period last year. Income before income tax for 2008 is $2,659,021 compared to $1,697,122 in the same period a year-earlier.

New Products Update:

CE Mark for SEER tissue resection device intended for initial use in liver oncology surgery. The CE Mark allows for the sale of the device in the European Union and all countries recognizing the mark. Shipments of the device have commenced in the last week.
Filed a 510(k) pre-notification application to the U.S. Food and Drug Administration (FDA) for the SEER.

Received a 510(k) clearance from the FDA to market the Company’s ICON GP to be used in general surgery.
FDA clearance and CE Mark to market MEG line of instruments in U.S. and abroad.

Advances continue to be made to the ICON GS Plasma generator with plans for a 510(k) submission in the near future.

Andrew Makrides, president of Bovie, stated, “Significant resources have been allocated to the development of new technologies and products over the past two years. The continued investment in SEER and Polarian demonstrates management’s goal of creating sustainable future growth from new products resulting in added value to shareholders.”

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

BOVIE MEDICAL CORPORATION CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE-MONTH PERIODS
	Three Months Ending September 30th		Three Months Ending September 30th
	2008	2007	2008	2007
Revenues	$7,295,793	$7,459,818	$20,958,672	$21,602,061
Cost of Sales	$4,062,424	$4,343,709	$12,238,925	$12,942,901
Gross Profit	$3,233,369	$3,116,109	$8,719,747	$8,659,160
Cost & Expense	$2,620,686	$2,405,278	$7,571,790	$6,966,862
Gain (loss) from Operations	$612,683	$710,831	$1,147,957	$1,692,298
Other Income (expense) Interest (net of expense)	$(15,244)	$34,086	$15,430	$101,323
Income Before Minority Interest and Income Taxes	$597,439	$744,917	2,659,021	$1,793,621
Minority Interest and Income Taxes	$(231,549)	$(273,281)	$(866,000)	$326,192
Net Income (loss) EPS (loss) Basic EPS (loss) Diluted	$365,890 .02 .02	$471,636 .03 .03	$1,793,021 .11 .10	$2,119,813 .14 .12
Weighted Average Shares Outstanding	16,067,979	15,388,073	15,998,150	15,284,033
Weighted Average Shares Adjusted for Dilutive Securities	17,820,155	17,699,654	17,731,492	17,669,657

Melville, New York, October 28, 2008 - Bovie Medical Corporation (the “Company”) (NYSE Alternext US: BVX), a manufacturer and marketer of electrosurgical products, today announced a CE Mark for its SEER tissue resection device intended for initial use in liver oncology surgery, allowing for the sale of the device in the European Union (EU) and all countries recognizing the CE Mark. The Company will immediately commence shipping the SEER to customers in the EU through its previously established network of distributors.

Additionally, the Company reported that it filed a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for the SEER.

Bovie Medical Corporation also received 510(k) clearance from the FDA to market its ICON GP generator to be used in general surgery and in conjunction with Bovie’s Polarian vessel sealing instruments. As of this date, a 510K application has not been filed for the Polarian instruments.

Andrew Makrides, president of Bovie stated, “These are significant milestones and are testaments to Bovie’s continued commitment to be an innovative player in the field of medical equipment. The Company is progressing in the development of its Polarian vessel sealing device and is developing prototypes for additional areas of surgery for the SEER. We believe the Polarian and the SEER product lines target new and significantly larger markets for Bovie.

As previously stated, discussions continue with larger companies regarding possible strategic partnerships involving some of the Company’s new product efforts.”

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, August 13, 2008 - Bovie Medical Corporation (the “Company”) (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced second quarter and six month results for the period ended June 30, 2008.

Second quarter revenues were $6,985,312 compared to $7,439,380 recorded in the same period of 2007. *Net income was $1,430,220 or $.08 per diluted share versus net income of $1,067,991 or $.06 per diluted share in the prior year. Revenues were impacted by a decline in OEM business; however based on orders received, the Company anticipates an increase in OEM business for the remainder of the year. Gross profit margin increased to 41.5% due to improved product mix relating to higher sales of products other than OEM. Research & Development costs rose 34% in the second quarter as a result of several products under development.

Six month revenues were $13,662,879 compared to $14,142,243 reported during the first six months of 2007. *Net income totaled $1,620,664 or $.09 per diluted share versus net income of $1,648,177 or $.09 per diluted share comparable period last year. The OEM sales decline was partially offset by a 29% increase in international sales in the first six months of 2008. This trend is expected to continue for the year.

*The Company realized other income totaling $1,504,580, which included $1,495,634 in the second quarter for acquiring intellectual property in a non-monetary exchange from a contract settlement as well as $8,946 interest income.

New Products Update:

FDA clearance and CE Mark to market MEG line of instruments in U.S. and abroad.
Initiated marketing of Canady Argon Plasma probes.
Submitted 510(k) application for ICON GP generator to be used in general surgery and in conjunction with the Company’s Polarian vessel sealing instruments currently being developed.
Made significant advances in the development of the SEER resection technology, for initial uses in liver surgery, to be followed by applications in additional surgical procedures characterized by attractive markets and margins.
Advances continue to be made in the ICON GS Plasma generator with plans for a 510(k) submission in the near future.

Andrew Makrides, president of Bovie, stated, “During the second quarter, Bovie made progress in the development of our new products highlighted by the acquisition of the SEER tissue resection device. The second half of 2008 will feature product development and new sales in the U.S. and abroad.”

In other news, the Company has secured a commitment for a $5.0 million line of credit from RBC Centura Bank. This new revolving line of credit will replace the prior $1.5 million unused credit line with Bank of America.

Gary Pickett, CFO of Bovie, commented that the Company considers this new banking relationship as another milestone. RBC Centura shares our vision in the future and the significant opportunities available to our Company.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

BOVIE MEDICAL CORPORATION CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX-MONTH PERIODS
	Three Months Ending June 30th		Three Months Ending December 31th (Unaudited)
	2008	2007	2008	2007
Revenues	$6,985,312	$7,439,380	$13,662,879	$14,142,243
Cost of Sales	$4,084,859	$4,401,413	$ 8,176,501	$ 8,599,192
Gross Profit	$2,900,453	$3,037,967	$5,486,378	$5,543,051
Cost & Expense	$2,655,011	$2,457,299	$4,951,983	$4,566,583
Gain (Loss) from Operations	$245,442	$580,668	$534,395	$976,468
Interest, Net	8,946	$33,649	30,673	$72,236
Gain on Cancellation of Agreement	1,495,634	-	1,495,634	-
Net Income (loss) Before Minority Interest and Income Taxes	$1,750,02	$614,317	$2,060,702	$1,048,704
Benefit (provision) for Income Taxes	$(319,802)	$(232,049	$(440,038)	$(421,146)
Net Income (loss) EPS (loss) Basic EPS (loss) Diluted	$1,430,220 .09 .08	$1,067,991 .07 .06	$1,620,664 .10 .09	$1,648,177 .11 .09
Weighted Average Shares Outstanding	16,002,841	15,346,673	15,962,852	15,317,816
Weighted Average Shares Adjusted for Dilutive Securities	17,803,069	17,752,431	17,708,156	17,781,383

Melville, New York, August 5, 2008 - Bovie Medical Corporation (the "Company") (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that the Food & Drug Administration has cleared its Modular Ergonomic Instruments (MEG Laparoscopic line), allowing the MEG line to be marketed and sold throughout the United States. The patent-pending modular forceps and accessories are designed to provide surgeons added comfort while reducing per-procedure costs through the reduction of inventory and obsolescence. The proprietary instruments offer a simpler assembly process for laparoscopic procedures. The MEG line is directed towards the laparoscopic market with estimated worldwide sales exceeding $425 million.

In other news, the Company recently filed a 510(k) application with the FDA for its ICON GP generator. The ICON GP will be used as a stand-alone advanced general purpose generator as well as in conjunction with the Company’s Polarian vessel sealing instruments currently under development.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, June 3, 2008 - Bovie Medical Corporation (the “Company”) (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced it recently launched the marketing of the Canady Argon Plasma Coagulation (APC) probes at the Digestive Disease Week (DDW) convention held in San Diego, CA. The DDW is the largest convention for gastroenterologists in the United States. Under a manufacturing and distribution agreement with Canady Technology signed last year, Bovie has been developing argon plasma probes for Canady Technology. The agreement allows Bovie to manufacture and distribute these Canady branded products through their GI distributors. The new probes incorporate several competitive advantages including price, a tip that prevents melting during prolonged use as well as several lengths and sizes in order to adapt to various procedures.

Bovie also announced it has submitted to the Food & Drug Administration (FDA) a 510(k) application for its Modular Ergonomic Instrument line (MEG line). The Company recently announced a CE Mark with the European Union (EU) allowing the MEG line to be marketed throughout the EU.

Management’s focus over the next several months will be to introduce new products into the marketplace; thus, expanding the Company’s future revenue sources.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, May 14, 2008 - Bovie Medical Corporation (the “Company”) (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced first quarter results for the period ended March 31, 2008.

First quarter revenues were $6,677,567 compared to $6,705,175 reported in the first quarter of 2007. Net income was $190,444 or $.01 per diluted share versus net income of $580,187 or $.03 per diluted share in the prior year. Revenues and net income in the first three months of the current fiscal year were impacted by a decline in OEM business and costs associated with the establishment of a European distribution network for the MEG laparoscopic line of instruments. The recently announced CE Mark allows the MEG to be marketed throughout the European Union. International sales increased 44% to a record $1.44 million versus $999,000 in the same period last year, which helped offset the decline in OEM business.

Andrew Makrides, president of Bovie, stated, “The costs associated with transforming Bovie from a company highly dependent on OEM customers to a proprietary product and sales company may impact short term results, as first quarter financials indicate. However, with the continued advancements in the development of Bovie’s MEG and Polarian hand held instruments, coupled with the recently acquired tissue resection technology from Boston Scientific Corporation, management remains optimistic that these products could significantly impact future revenues.”

Mr. Makrides added, “After a period of new product development, we have entered a new phase for Bovie Medical. Over the course of the next several months, we anticipate submitting several new products to the FDA, including our MEG laparoscopic line of instruments, an oncology tissue resection device, the Polarian vessel sealing instrument and generator and our ICON GS Plasma (J-Plasma) generator. The potential niche markets for these products are significantly larger than markets the Company currently serves.”

As the Company progresses towards its goal of becoming a dynamic, strong growth and high margin oriented company known for its proprietary technologies, management believes this will create long term increased shareholder value.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, May 5, 2008 - Bovie Medical Corporation (the “Company”) (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced a CE Mark for its Modular Ergonomic Instruments (MEG laparoscopic line), allowing the MEG Laparoscopic line to be marketed throughout the European Union. The patent-pending modular forceps and accessories are designed to provide surgeons added comfort while reducing per-procedure costs through the reduction of inventory and obsolescence. The proprietary instruments offer a simpler assembly process for laparoscopic procedures. The MEG Laparoscopic line is directed towards the laparoscopic market with estimated worldwide size exceeding $425 million. The Company anticipates shipments of the instrument line to commence during the second quarter of 2008. Mr. Johan Segers of Antwerp, Belgium, was appointed Bovie’s Director of Sales and Marketing for Europe and the Middle East. Mr. Segers has a Masters Degree in Health Care Sciences from the University of Brussels and has over 25 years of successful distribution experience with US, Israeli and European medical companies. Mr. Segers is in the process of recruiting and training a network of talented distributors throughout the EU and Middle East markets as well as retaining key surgeon opinion leaders for the MEG Laparoscopic line of instruments as well as other Bovie products. Andrew Makrides, president of Bovie Medical, stated, “The CE Mark confirms compliance with essential requirements of the European Medical Devices Directive and represents a product development milestone for our company. We look to build on this success with additional new products coming to market in the near future.” This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings. www.boviemedical.com "

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, New York, May 1, 2008 - Bovie Medical Corporation (the "Company") (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced it has signed an agreement with Boston Scientific Corporation (NYSE: BSX) to acquire technology, patents, and assets related to the use of conductive sintered steel as an electrode for radio frequency (RF) cutting and coagulation, intended to lower blood loss, quicken procedure times and provide cost savings for hospitals. Potential fields of therapy for the technology acquired include liver, pancreatic and kidney tumor therapies along with orthopedic and blood vessel sealing. The process involves delivery of RF current and sterile saline for resection, hemostatic sealing and coagulation in open and laparoscopic surgery. The worldwide market size for the liver and orthopedic market is expected to total $500 million in 2009.

This agreement replaces a previously signed distribution and marketing agreement between the Companies for the technology’s use in Boston Scientifics’ oncology business. The original development and manufacturing agreement signed in 2007 required Bovie to develop and manufacture certain products using Boston Scientifics’ intellectual property. Bovie intends to finalize the development and commercialization of the technology. As part of the agreement, Bovie granted a license to Boston Scientific limited until 2016 to uses outside of those fields listed above.

Andrew Makrides, president of Bovie Medical Corporation commented, "This agreement further enhances Bovie’s intellectual property portfolio, while creating new significant market opportunities for the Company. Adding strength to Bovie’s new product line, Mr. Bob Rioux, who was at the forefront of the Boston Scientific tissue resection program, is joining Bovie as Vice President of Advanced Resection Technologies. Mr. Rioux’s combination of technical and marketing skills makes him ideally suited to commercialize these new products."

Mr. Makrides concluded, "With the expected launch of the MEG line in Europe, management’s goal of transforming Bovie into a leading technology medical device company has commenced. While these initiatives may, in the short term, impact our bottom line, management believes we are building a solid foundation for increasing shareholder value."

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087

Melville, April 14, 2008 - Bovie Medical Corporation (the "Company") (Amex: BVX), a manufacturer and marketer of electrosurgical products, reported that it named Steve Livneh and Steve MacLaren to serve on the Company's Board of Directors effective April 8, 2008.

Steve Livneh became President of Bovie Canada in October 2006 following the asset purchase of certain intellectual properties by Bovie from LICAN Development of Ontario, Canada. Mr. Livneh is a mechanical engineer and inventor and has developed and manufactured varied products, including aerial munitions, consumer goods, irrigation and hydraulic devices and guidance systems. During the past several years he has been engaged in developing endoscopic electrosurgery instruments, targeting the general surgery, gynecology, urology and thoracic surgery markets. Mr. Livneh has also been appointed to be Chief Technology Officer of Bovie Medical Corporation, effective April 8, 2008.

Steven MacLaren holds a BSBA degree in accounting from Ohio State University. He is currently the principal owner of Ronin Business Consulting which he started in 2004 and has provided consulting services for Bovie Medical since August 2005. Previous to this he served as the CFO and a technical currency trader of Capital Management Group, LLC, an investment company located in Naples, FL. Mr. MacLaren has a history with the company as he served as Bovie Medical’s Controller from 1996 through 2001. He has extensive knowledge in technical analysis techniques and trading systems applied in both U.S. equity and foreign currency markets. In addition, Mr. MacLaren has previous public accounting and business ownership experience.

Andrew Makrides, president of Bovie Medical, stated, "We are extremely pleased to welcome Messers. Livneh and MacLaren to our board. I am confident that their individual professionalism, experience and personal integrity will enable them to contribute meaningfully to our strong commitment to serve Bovie shareholders."

This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Contact Information
Investor Relations:
John Aneralla
Buttonwood Advisory Group, Inc.
Phone (800) 940-9087